European review for medical and pharmacological sciences
-
Eur Rev Med Pharmacol Sci · Jun 2019
MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
To investigate the role of micro ribonucleic acid (miR)-124 in drug resistance of non-small cell lung cancer (NSCLC), and to explore its underlying mechanism. ⋯ MiR-124 regulates the sensitivity of NSCLC to cisplatin. Moreover, it inhibits the invasion and metastasis capacities through targeting STAT3, which can serve as a therapeutic target for cisplatin-based chemotherapy resistance of NSCLC.
-
Eur Rev Med Pharmacol Sci · Jun 2019
Retracted PublicationLong noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2.
Drug-resistance remains a huge problem in the therapy of malignant tumors including non-small cell lung cancer (NSCLC). Several researches have proved that long noncoding RNAs (lncRNAs) contributes to drug-resistance in NSCLC. LncRNA LUCAT1 was explored to identify how it functions in the cisplatin-resistance of NSCLC patients. ⋯ We suggest that LUCAT1 regulates cell cycle, cell apoptosis of NSCLC cells and the resistance to cisplatin through targeting IGF-2 and could be a possible target for NSCLC treatment.